Guangzhou Innogen Pharm Grp Co (2591) fair value: what the stock is really worth
As of Nov 13, 2026: fair value (intrinsic value) of Guangzhou Innogen Pharm Grp Co stock HK$3.15, price HK$3.55, that is 11.3% below the price, quality 33 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Guangzhou Innogen Pharm Grp Co
2591 · HKExpensive (fair value 11% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.
How to read this chart
15‑month range HK$3.09 – HK$57.25 · fair‑value band HK$2.36 – HK$3.94 · the HK$3.55 price screens above the HK$3.15 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.
Every Wednesday you see whether Guangzhou Innogen Pharm Grp Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Guangzhou Innogen Pharmaceutical Group Co., Ltd engages in the development of drug engaged in the research, development and commercialization of pharmaceutical products.
Show moreShow less
The company's products are used for the treatment of metabolic diseases, including diabetes, obesity and overweight, and MASH; and other major central nervous system diseases. The company was incorporated in 2014 and is based in Shanghai, China.
Stock analysis
Guangzhou Innogen Pharm Grp Co (2591) currently trades at HK$3.55, while our estimate is HK$3.15, 11% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: HK$2.36 (bear) to HK$3.94 (bull), the price of HK$3.55 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
Guangzhou Innogen Pharm Grp Co reported revenue of 128M CNY in FY2025 versus 0 CNY in FY2023. Reported net income was −333M CNY in FY2025.
Key figures
Market cap HK$1.6B (≈ $207M) Micro · P/S ratio 9.58 · Return on equity −41.2% · Return on assets (EBIT) −39.5% (4-year average) · Operating margin −153% · Revenue (TTM) 153M CNY · Revenue growth (YoY) +38.6% · Free cash flow −318M CNY.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).
What moves the price
The share trades about 92% below its 52-week high and 15% above its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −11%, 2591 screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Compare Guangzhou Innogen Pharm Grp Co with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Price/FCF by industry
- Debt-to-equity by industry
- PEG screener for stocks with fair value
- Undervalued stocks: Hong Kong Stocks
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $955.47 | $1,275 | +33% | vs 2591 |
| Vertex Pharmaceuticals Incorporated VRTX | $538.60 | $592.46 | +10% | vs 2591 |
| Samsung Biologics Co 207940 | 1,411,000 KRW | 1,552,100 KRW | +10% | vs 2591 |
| Genmab A/S GMAB | kr 3,448 | kr 3,793 | +10% | vs 2591 |
| argenx SE ARGX | $960.04 | $908.40 | −5% | vs 2591 |
| CSL Limited CSL | A$202.52 | A$185.51 | −8% | vs 2591 |
| Moderna, Inc MRNA | $223.37 | $139.99 | −37% | vs 2591 |
| Revolution Medicines, Inc RVMD | $172.29 | $88.78 | −48% | vs 2591 |
| Celltrion, Inc 068270 | 214,000 KRW | 74,945 KRW | −65% | vs 2591 |
| Royalty Pharma plc RPRX | $69.31 | $19.01 | −73% | vs 2591 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Guangzhou Innogen Pharm Grp Co (2591) overvalued or undervalued?
What is the fair value of 2591?
What is the quality score of 2591?
What is the price target for Guangzhou Innogen Pharm Grp Co (2591)?
What is the Guangzhou Innogen Pharm Grp Co stock forecast for 2026?
What is the revenue of Guangzhou Innogen Pharm Grp Co (2591)?
What is the intrinsic value of Guangzhou Innogen Pharm Grp Co (2591)?
Is Guangzhou Innogen Pharm Grp Co stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 2591?
How much is Guangzhou Innogen Pharm Grp Co worth?
What do the bullish and bearish scenarios say about 2591?
How solid is the balance sheet of Guangzhou Innogen Pharm Grp Co (2591)?
How far is 2591 from its 52-week high?
Which stocks are comparable to Guangzhou Innogen Pharm Grp Co?
Is Guangzhou Innogen Pharm Grp Co stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Guangzhou Innogen Pharm Grp Co (2591)?
What should I pay attention to with Guangzhou Innogen Pharm Grp Co right now?
Key figures of Guangzhou Innogen Pharm Grp Co
How large is the market capitalisation of Guangzhou Innogen Pharm Grp Co (2591)?
What is the P/S ratio of Guangzhou Innogen Pharm Grp Co (2591)?
What is the return on equity of Guangzhou Innogen Pharm Grp Co (2591)?
What is the EBIT return on assets of Guangzhou Innogen Pharm Grp Co (2591)?
What is the operating margin of Guangzhou Innogen Pharm Grp Co (2591)?
How fast is revenue growing at Guangzhou Innogen Pharm Grp Co (2591)?
How much free cash flow does Guangzhou Innogen Pharm Grp Co (2591) generate?
How much net cash does Guangzhou Innogen Pharm Grp Co (2591) hold?
Watch Guangzhou Innogen Pharm Grp Co in the live analysis
One click puts Guangzhou Innogen Pharm Grp Co on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.